Edmond de Rothschild Investment Partners, which has just celebrated its 10th anniversary, has revealed plans to raise EUR500m over the next four years and increase net asset under management to EUR1.3bn.
Edmond de Rothschild Investment Partners currently manages EUR1bn focusing on growth capital and life sciences in France and Europe.
Despite a difficult environment since 2008, institutional and private investors have continued to support the teams in successfully raising three funds: BioDiscovery 3, Winch 2 and Cabestan. BioDiscovery 4 is also expected to reach its EUR200m target very soon.
Edmond de Rothschild Investment Partners aims to raise EUR500m over the next four years and to increase net assets under management to EUR1.3bn. To reach this goal, the company will continue to expand its investment strategy to SMEs across Europe and broaden its investor base.
"Since Edmond de Rothschild Investment Partners was founded, the capital development team has accompanied more than 70 entrepreneurs in ambitious projects including industrial investments, international development and external growth. Our portfolio companies are mainly French sector leaders like Nexira, Sergent Major and Voyageurs du Monde.” says Pierre-Yves Poirier, partner, capital development.
Olivier Litzka, partner, life sciences, says: "Since 2005, we have invested via our BioDiscovery 2 and 3 funds more than EUR200m in 25 innovative European biotech and medtech companies which have played a major role in discovering new treatments for serious illnesses. We have sold six of these companies through trade sales and two have been listed. Providing investors with access to a fascinating and meaningful sector through high-performance funds is doubly satisfying."
